June 2015
Volume 56, Issue 7
Jump To...
Free
ARVO Annual Meeting Abstract  |   June 2015
The Natural History of the Progression of Atrophy secondary to Stargardt Disease studies (ProgStar): yearly progression rate of atrophic lesions in the retrospective study
Rupert Wolfgang Strauss; Beatriz E Munoz; Alexander Ho; Yulia Wolfson; Srinivas R Sadda; Xiangrong Kong; Sheila K West; Hendrik P Scholl; ProgStar study group
Author Affiliations & Notes
  • Rupert Wolfgang Strauss
    Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD
    Ophthalmology, Medical University Graz, Graz, Austria
  • Beatriz E Munoz
    Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD
  • Alexander Ho
    Doheny Image Reading Center, Los Angeles, CA
  • Yulia Wolfson
    Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD
  • Srinivas R Sadda
    Doheny Image Reading Center, Los Angeles, CA
  • Xiangrong Kong
    Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD
  • Sheila K West
    Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD
  • Hendrik P Scholl
    Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD
  • Footnotes
    Commercial Relationships Rupert Strauss, None; Beatriz Munoz, None; Alexander Ho, None; Yulia Wolfson, None; Srinivas Sadda, Carl Zeiss Meditech (C), Carl Zeiss Meditech (F), Carl Zeiss Meditech (R), Optos (C), Optos (F), Optos (R); Xiangrong Kong, None; Sheila West, None; Hendrik Scholl, QLT Inc. (C), QLT Inc. (F), Sanofi-Fovea Pharmaceuticals (C), Vision Medicines, Inc. (C)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 894. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      The Natural History of the Progression of Atrophy secondary to Stargardt Disease studies (ProgStar): yearly progression rate of atrophic lesions in the retrospective study
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      Rupert Wolfgang Strauss, Beatriz E Munoz, Alexander Ho, Yulia Wolfson, Srinivas R Sadda, Xiangrong Kong, Sheila K West, Hendrik P Scholl, ProgStar study group; The Natural History of the Progression of Atrophy secondary to Stargardt Disease studies (ProgStar): yearly progression rate of atrophic lesions in the retrospective study. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):894.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract
 
Purpose
 

The multicenter ProgStar studies aim to characterize the natural history of Stargardt disease (STGD) and to develop new outcome measures for clinical trials. The yearly rate of progression of STGD using the growth of atrophic lesions as measured by fundus autofluorescence (AF) imaging is the primary endpoint.

 
Methods
 

FAF images from genetically confirmed STGD patients were sent from the nine participating sites to a central reading center (Doheny Image Reading Center, CA) and areas of definitely decreased AF (DDAF), well-demarcated questionably decreased AF (WD-QDAF), and poorly demarcated questionably decreased AF (PD-QDAF) were outlined and quantified. Progression rates were estimated from linear mixed models with time as the independent variable. The models include random effects for the intercept, the slope of time, and the eye.

 
Results
 

442 study eyes of 243 study participants were enrolled in the retrospective study and images from 204 eyes of 111 participants (38.4 % male, 61.6 % female) were graded for two (n=159) or three (n= 45) visits. Mean age at first visit was 31.3 years, observational time interval was 3.3 years (SD 1.5 years).<br /> At first visit, DDAF was present in 73 (36%) of the eyes, mean lesion size 3.36 (sd 4.1) mm2; WD-QDAF in 55 (27%), mean lesion size 1.35 (sd 1.69) mm2, and PD-QDAF in 122 (60%) mean lesion size 170 (sd 1.87) mm2.<br /> The estimated progression of DDAF in the 73 eyes was 0.54 mm2 per year (p<0.001).<br /> The estimated cumulative incidence of DDAF areas in the 131 eyes without DDAF at first visit was 24.4% by the end of the follow-up.

 
Conclusions
 

FAF may serve as a monitoring tool for interventional clinical trials in STGD that aim to slow down disease progression. Additional outcome measures for special subtypes of patients will be evaluated in the ProgStar studies.  

Image not available
View OriginalDownload Slide
Image not available
View OriginalDownload Slide

 
The Association for Research in Vision and Ophthalmology
Copyright © 2024 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept